BioMedicines (company) | Wikipedia audio article
Channel: wikipedia tts
Date: 2019-05-02

This is an audio version of the Wikipedia Article:
https://en.wikipedia.org/wiki/Intarcia_Therapeutics


00:01:24 Investors
00:02:45 Notes
00:02:54 External links



Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone.

Listen on Google Assistant through Extra Audio:
https://assistant.google.com/services/invoke/uid/0000001a130b3f91
Other Wikipedia audio articles at:
https://www.youtube.com/results?search_query=wikipedia+tts
Upload your own Wikipedia articles through:
https://github.com/nodef/wikipedia-tts
Speaking Rate: 0.975829761956448
Voice name: en-AU-Wavenet-A


"I cannot teach anybody anything, I can only make them think."
- Socrates


SUMMARY
=======
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware.  It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system.In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively.  By 2012, Kurt Graves had replaced Karling Leung as President and CEO. Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012.As of 2016, Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment".  Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System, "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides".